First Time Loading...

Avidity Biosciences Inc
NASDAQ:RNA

Watchlist Manager
Avidity Biosciences Inc Logo
Avidity Biosciences Inc
NASDAQ:RNA
Watchlist
Price: 23.83 USD -5.02% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

RNA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). [ Read More ]

The intrinsic value of one RNA stock under the Base Case scenario is 8.57 USD. Compared to the current market price of 23.83 USD, Avidity Biosciences Inc is Overvalued by 64%.

Key Points:
RNA Intrinsic Value
Base Case
8.57 USD
Overvaluation 64%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Avidity Biosciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling RNA stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Avidity Biosciences Inc

Provide an overview of the primary business activities
of Avidity Biosciences Inc.

What unique competitive advantages
does Avidity Biosciences Inc hold over its rivals?

What risks and challenges
does Avidity Biosciences Inc face in the near future?

Has there been any significant insider trading activity
in Avidity Biosciences Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Avidity Biosciences Inc.

Provide P/S
for Avidity Biosciences Inc.

Provide P/E
for Avidity Biosciences Inc.

Provide P/OCF
for Avidity Biosciences Inc.

Provide P/FCFE
for Avidity Biosciences Inc.

Provide P/B
for Avidity Biosciences Inc.

Provide EV/S
for Avidity Biosciences Inc.

Provide EV/GP
for Avidity Biosciences Inc.

Provide EV/EBITDA
for Avidity Biosciences Inc.

Provide EV/EBIT
for Avidity Biosciences Inc.

Provide EV/OCF
for Avidity Biosciences Inc.

Provide EV/FCFF
for Avidity Biosciences Inc.

Provide EV/IC
for Avidity Biosciences Inc.

Show me price targets
for Avidity Biosciences Inc made by professional analysts.

What are the Revenue projections
for Avidity Biosciences Inc?

How accurate were the past Revenue estimates
for Avidity Biosciences Inc?

What are the Net Income projections
for Avidity Biosciences Inc?

How accurate were the past Net Income estimates
for Avidity Biosciences Inc?

What are the EPS projections
for Avidity Biosciences Inc?

How accurate were the past EPS estimates
for Avidity Biosciences Inc?

What are the EBIT projections
for Avidity Biosciences Inc?

How accurate were the past EBIT estimates
for Avidity Biosciences Inc?

Compare the revenue forecasts
for Avidity Biosciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Avidity Biosciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Avidity Biosciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Avidity Biosciences Inc compared to its peers.

Compare the P/E ratios
of Avidity Biosciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Avidity Biosciences Inc with its peers.

Analyze the financial leverage
of Avidity Biosciences Inc compared to its main competitors.

Show all profitability ratios
for Avidity Biosciences Inc.

Provide ROE
for Avidity Biosciences Inc.

Provide ROA
for Avidity Biosciences Inc.

Provide ROIC
for Avidity Biosciences Inc.

Provide ROCE
for Avidity Biosciences Inc.

Provide Gross Margin
for Avidity Biosciences Inc.

Provide Operating Margin
for Avidity Biosciences Inc.

Provide Net Margin
for Avidity Biosciences Inc.

Provide FCF Margin
for Avidity Biosciences Inc.

Show all solvency ratios
for Avidity Biosciences Inc.

Provide D/E Ratio
for Avidity Biosciences Inc.

Provide D/A Ratio
for Avidity Biosciences Inc.

Provide Interest Coverage Ratio
for Avidity Biosciences Inc.

Provide Altman Z-Score Ratio
for Avidity Biosciences Inc.

Provide Quick Ratio
for Avidity Biosciences Inc.

Provide Current Ratio
for Avidity Biosciences Inc.

Provide Cash Ratio
for Avidity Biosciences Inc.

What is the historical Revenue growth
over the last 5 years for Avidity Biosciences Inc?

What is the historical Net Income growth
over the last 5 years for Avidity Biosciences Inc?

What is the current Free Cash Flow
of Avidity Biosciences Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Avidity Biosciences Inc.

Financials

Balance Sheet Decomposition
Avidity Biosciences Inc

Current Assets 611.3m
Cash & Short-Term Investments 595.4m
Receivables 1.1m
Other Current Assets 14.9m
Non-Current Assets 17.2m
PP&E 16.7m
Other Non-Current Assets 596k
Current Liabilities 80.7m
Accounts Payable 8.8m
Accrued Liabilities 43.5m
Other Current Liabilities 28.4m
Non-Current Liabilities 47.1m
Other Non-Current Liabilities 47.1m
Efficiency

Earnings Waterfall
Avidity Biosciences Inc

Revenue
9.6m USD
Operating Expenses
-245.2m USD
Operating Income
-235.6m USD
Other Expenses
23.4m USD
Net Income
-212.2m USD

Free Cash Flow Analysis
Avidity Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

RNA Profitability Score
Profitability Due Diligence

Avidity Biosciences Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Exceptional Revenue Growth Forecast
Positive 3-Years Revenue Growth
Positive 1-Year Revenue Growth
36/100
Profitability
Score

Avidity Biosciences Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

RNA Solvency Score
Solvency Due Diligence

Avidity Biosciences Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
64/100
Solvency
Score

Avidity Biosciences Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RNA Price Targets Summary
Avidity Biosciences Inc

Wall Street analysts forecast RNA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RNA is 47.65 USD with a low forecast of 33.33 USD and a high forecast of 74.55 USD.

Lowest
Price Target
33.33 USD
40% Upside
Average
Price Target
47.65 USD
100% Upside
Highest
Price Target
74.55 USD
213% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

RNA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

RNA Price
Avidity Biosciences Inc

1M 1M
-1%
6M 6M
+351%
1Y 1Y
+37%
3Y 3Y
-5%
5Y 5Y
-16%
10Y 10Y
-16%
Annual Price Range
23.83
52w Low
4.87
52w High
26.87
Price Metrics
Average Annual Return -10.7%
Standard Deviation of Annual Returns 4.1%
Max Drawdown -86%
Shares Statistics
Market Capitalization 1.9B USD
Shares Outstanding 79 719 504
Percentage of Shares Shorted 12.66%

RNA Return Decomposition
Main factors of price return

What is price return decomposition?

RNA News

Other Videos

Company Profile

Avidity Biosciences Inc Logo
Avidity Biosciences Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.9B USD

Dividend Yield

0%

Description

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). The company is headquartered in San Diego, California and currently employs 125 full-time employees. The company went IPO on 2020-06-12. The firm utilizes its AOC platform to design, engineer and develop therapeutics, which combine specificity of monoclonal antibodies (mAbs), with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with such therapeutics. Its lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1 (DM1) a rare monogenic muscle disease. The Company’s advancing and expanding pipeline also includes AOC 1044, the lead of three programs for the treatment of Duchenne Muscular Dystrophy (DMD), and AOC 1020, designed to treat facioscapulohumeral muscular dystrophy (FSHD). AOC 1020 consists of its mAb, which is designed to bind to TfR1 conjugated with a siRNA targeted to DUX4 mRNA to be administered as an intravenous infusion.

Contact

CALIFORNIA
San Diego
10578 Science Center Drive, Suite 125
+18584017900.0
http://www.aviditybiosciences.com/

IPO

2020-06-12

Employees

125

Officers

Co-Founder & Chairman
Dr. Troy Edward Wilson J.D., Ph.D.
President, CEO & Director
Ms. Sarah Boyce
Chief Financial & Chief Business Officer
Mr. Michael F. MacLean
Chief Scientific & Technical Officer
Dr. W. Michael Flanagan Ph.D.
Chief Human Resources Officer
Ms. Teresa McCarthy
Chief Strategy Officer
Mr. Eric B. Mosbrooker
Show More
Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers
Prof. Mark E. Davis
Scientific Founder & Member of Scientific Advisory Board
Dr. Frank P. McCormick Ph.D.
VP of Investor Relation & Corporate Communication
Mr. Geoffrey M. Grande C.F.A.
VP of Intellectual Property, General Counsel & Secretary
Dr. John W. Wallen III
Show Less

See Also

Discover More
What is the Intrinsic Value of one RNA stock?

The intrinsic value of one RNA stock under the Base Case scenario is 8.57 USD.

Is RNA stock undervalued or overvalued?

Compared to the current market price of 23.83 USD, Avidity Biosciences Inc is Overvalued by 64%.